[go: up one dir, main page]

WO2018153508A3 - Sulfoximine glycosidase inhibitors - Google Patents

Sulfoximine glycosidase inhibitors Download PDF

Info

Publication number
WO2018153508A3
WO2018153508A3 PCT/EP2017/071385 EP2017071385W WO2018153508A3 WO 2018153508 A3 WO2018153508 A3 WO 2018153508A3 EP 2017071385 W EP2017071385 W EP 2017071385W WO 2018153508 A3 WO2018153508 A3 WO 2018153508A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulfoximine
glycosidase inhibitors
glycosidase
inhibitors
tauopathies
Prior art date
Application number
PCT/EP2017/071385
Other languages
French (fr)
Other versions
WO2018153508A2 (en
Inventor
Anna Quattropani
Santosh S. Kulkarni
Awadut Gajendra Giri
Original Assignee
Asceneuron S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/054268 external-priority patent/WO2017144633A1/en
Priority claimed from PCT/EP2017/054280 external-priority patent/WO2017144639A1/en
Priority to MX2019010085A priority Critical patent/MX2019010085A/en
Priority to KR1020237005097A priority patent/KR102620279B1/en
Priority to KR1020197027278A priority patent/KR20190118184A/en
Priority to AU2017400271A priority patent/AU2017400271B2/en
Priority to US16/488,139 priority patent/US11261183B2/en
Priority to BR112019017514-8A priority patent/BR112019017514B1/en
Priority to EA201991697A priority patent/EA201991697A1/en
Priority to CA3053200A priority patent/CA3053200C/en
Application filed by Asceneuron S.A. filed Critical Asceneuron S.A.
Priority to EP17758140.2A priority patent/EP3585783A2/en
Priority to PCT/EP2017/071385 priority patent/WO2018153508A2/en
Priority to CN201780089984.7A priority patent/CN110770226B/en
Priority to JP2019545961A priority patent/JP7082446B2/en
Priority to SG11201907774VA priority patent/SG11201907774VA/en
Publication of WO2018153508A2 publication Critical patent/WO2018153508A2/en
Publication of WO2018153508A3 publication Critical patent/WO2018153508A3/en
Priority to IL268501A priority patent/IL268501A/en
Priority to ZA2019/05405A priority patent/ZA201905405B/en
Priority to US17/552,100 priority patent/US12157734B2/en
Priority to US18/913,906 priority patent/US20250115604A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
PCT/EP2017/071385 2016-02-25 2017-08-24 Sulfoximine glycosidase inhibitors WO2018153508A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
JP2019545961A JP7082446B2 (en) 2016-02-25 2017-08-24 Sulfoxyimine glycosidase inhibitor
SG11201907774VA SG11201907774VA (en) 2017-02-24 2017-08-24 Sulfoximine glycosidase inhibitors
EP17758140.2A EP3585783A2 (en) 2016-02-25 2017-08-24 Sulfoximine glycosidase inhibitors
KR1020197027278A KR20190118184A (en) 2016-02-25 2017-08-24 Sulfoximine glycosidase inhibitors
AU2017400271A AU2017400271B2 (en) 2017-02-24 2017-08-24 Sulfoximine glycosidase inhibitors
US16/488,139 US11261183B2 (en) 2016-02-25 2017-08-24 Sulfoximine glycosidase inhibitors
BR112019017514-8A BR112019017514B1 (en) 2017-02-24 2017-08-24 SULFOXIMIN COMPOUND, MIXTURE, METHOD FOR INHIBITING A GLUCOSIDASE, AND PHARMACEUTICAL COMPOSITION
EA201991697A EA201991697A1 (en) 2016-02-25 2017-08-24 SULFOXYMINE Glycosidase Inhibitors
CA3053200A CA3053200C (en) 2016-02-25 2017-08-24 Sulfoximine glycosidase inhibitors
MX2019010085A MX2019010085A (en) 2017-02-24 2017-08-24 Sulfoximine glycosidase inhibitors.
KR1020237005097A KR102620279B1 (en) 2016-02-25 2017-08-24 Sulfoximine glycosidase inhibitors
PCT/EP2017/071385 WO2018153508A2 (en) 2017-02-24 2017-08-24 Sulfoximine glycosidase inhibitors
CN201780089984.7A CN110770226B (en) 2016-02-25 2017-08-24 Sulfoximine glycosidase inhibitors
IL268501A IL268501A (en) 2016-02-25 2019-08-05 Sulfoximine glycosidase inhibitors
ZA2019/05405A ZA201905405B (en) 2016-02-25 2019-08-15 Sulfoximine glycosidase inhibitors
US17/552,100 US12157734B2 (en) 2016-02-25 2021-12-15 Sulfoximine glycosidase inhibitors
US18/913,906 US20250115604A1 (en) 2016-02-25 2024-10-11 Sulfoximine glycosidase inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2017/054268 WO2017144633A1 (en) 2016-02-25 2017-02-24 Glycosidase inhibitors
PCT/EP2017/054280 WO2017144639A1 (en) 2016-02-25 2017-02-24 Glycosidase inhibitors
EPPCT/EP2017/054280 2017-02-24
EPPCT/EP2017/054268 2017-02-24
PCT/EP2017/071385 WO2018153508A2 (en) 2017-02-24 2017-08-24 Sulfoximine glycosidase inhibitors

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2017/054280 Continuation-In-Part WO2017144639A1 (en) 2016-02-25 2017-02-24 Glycosidase inhibitors
PCT/EP2017/054268 Continuation-In-Part WO2017144633A1 (en) 2016-02-25 2017-02-24 Glycosidase inhibitors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/488,139 A-371-Of-International US11261183B2 (en) 2016-02-25 2017-08-24 Sulfoximine glycosidase inhibitors
US17/552,100 Division US12157734B2 (en) 2016-02-25 2021-12-15 Sulfoximine glycosidase inhibitors

Publications (2)

Publication Number Publication Date
WO2018153508A2 WO2018153508A2 (en) 2018-08-30
WO2018153508A3 true WO2018153508A3 (en) 2019-02-21

Family

ID=59686981

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2017/071384 WO2018153507A1 (en) 2016-02-25 2017-08-24 Substituted dihydrobenzofuran glycosidase inhibitors
PCT/EP2017/071385 WO2018153508A2 (en) 2016-02-25 2017-08-24 Sulfoximine glycosidase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/071384 WO2018153507A1 (en) 2016-02-25 2017-08-24 Substituted dihydrobenzofuran glycosidase inhibitors

Country Status (5)

Country Link
EP (2) EP3585779A1 (en)
AU (1) AU2017400271B2 (en)
MX (1) MX2019010085A (en)
SG (1) SG11201907774VA (en)
WO (2) WO2018153507A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201701315VA (en) 2014-08-28 2017-03-30 Asceneuron Sa Glycosidase inhibitors
WO2017144633A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Glycosidase inhibitors
MX2018010191A (en) 2016-02-25 2019-05-20 Asceneuron S A Glycosidase inhibitors.
AU2017222962B2 (en) 2016-02-25 2021-03-25 Asceneuron S. A. Acid addition salts of piperazine derivatives
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
MA53429A (en) * 2018-08-22 2022-03-30 Asceneuron Sa SUCCINATE AND FUMARATE ACID ADDITIONAL SALTS OF PIPERAZINE DERIVATIVES USEFUL AS GLYCOSIDASE INHIBITORS
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
WO2025131275A1 (en) 2023-12-20 2025-06-26 Asceneuron Sa (2-(4-(1-(benzo[d]thiazol-5-yl)ethyl)piperazin-1 -yl)pyrimidin-5-yl)(imino)(methyl)-lamda6-sulfanone for use in the treatment of colitis, parkinson disease, tauopathy, als and alzheimer's disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094799A2 (en) * 2001-05-22 2002-11-28 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
WO2014159234A1 (en) * 2013-03-14 2014-10-02 Merck Patent Gmbh Glycosidase inhibitors
WO2016030443A1 (en) * 2014-08-28 2016-03-03 Asceneuron Sa Glycosidase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127996C (en) 1963-11-19
DE1595923A1 (en) 1965-02-20 1969-11-27 Merck Ag E 1-Aralkyl-4- (thiazolyl-2) -piperazines and processes for their preparation
ATE294173T1 (en) 1997-10-24 2005-05-15 Neurogen Corp 1-(2-NAPHTHYL) AND 1-(2-AZANAPHTHYL)-4-(1-PHENYLMETHYL)PIPERAZINE AS DOPAMINE D4 SUBTYPE LIGANDS
WO2005110982A2 (en) * 2004-04-07 2005-11-24 Neurogen Corporation Substituted 1-benzyl-4-substituted piperazine analogues
CA2661582C (en) 2006-08-31 2015-09-29 Simon Fraser University Selective glycosidase inhibitors and uses thereof
ES2448870T3 (en) 2007-10-26 2014-03-17 Janssen Pharmaceutica, N.V. Quinoline derivatives as PARP inhibitors
US9522883B2 (en) 2012-08-31 2016-12-20 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
AU2017222962B2 (en) * 2016-02-25 2021-03-25 Asceneuron S. A. Acid addition salts of piperazine derivatives
MX2018010191A (en) * 2016-02-25 2019-05-20 Asceneuron S A Glycosidase inhibitors.
WO2017144633A1 (en) * 2016-02-25 2017-08-31 Asceneuron S. A. Glycosidase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094799A2 (en) * 2001-05-22 2002-11-28 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
WO2014159234A1 (en) * 2013-03-14 2014-10-02 Merck Patent Gmbh Glycosidase inhibitors
WO2016030443A1 (en) * 2014-08-28 2016-03-03 Asceneuron Sa Glycosidase inhibitors

Also Published As

Publication number Publication date
WO2018153508A2 (en) 2018-08-30
WO2018153507A1 (en) 2018-08-30
SG11201907774VA (en) 2019-09-27
EP3585783A2 (en) 2020-01-01
AU2017400271B2 (en) 2020-09-24
MX2019010085A (en) 2019-11-21
AU2017400271A1 (en) 2019-08-22
EP3585779A1 (en) 2020-01-01

Similar Documents

Publication Publication Date Title
MX2018010192A (en) Glycosidase inhibitors.
WO2018153508A3 (en) Sulfoximine glycosidase inhibitors
MX2018010191A (en) Glycosidase inhibitors.
ZA201701299B (en) Glycosidase inhibitors
MX2022012317A (en) Oxysterols and methods of use thereof.
SA520412335B1 (en) Oxy-fluoropiperidine derivatives as kinase inhibitor
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
SG11201901061QA (en) Heterocyclic compound
EP4292650A3 (en) Heterocyclic compounds as immunomodulators
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
MY208662A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
PH12018500061A1 (en) Oxysterols and methods of use thereof
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
SA519402288B1 (en) Pyrimidine compound and pharmaceutical use thereof
GEP20227406B (en) Chromane monobactam compounds for the treatment of bacterial infections
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
MY209256A (en) Compounds affecting pigment production and use thereof for treatment of bacterial diseases
WO2018194181A8 (en) Heterocyclic compounds useful as modulators of acetylcholine receptors
MX2021015514A (en) Heterocyclic compound.
MX2019006768A (en) Antimicrobial peptides.
PH12020550222A1 (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
MY193239A (en) Novel b-lactamase inhibitors
MX374568B (en) Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17758140

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3053200

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017400271

Country of ref document: AU

Date of ref document: 20170824

Kind code of ref document: A

Ref document number: 2019545961

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019017514

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20197027278

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017758140

Country of ref document: EP

Effective date: 20190924

ENP Entry into the national phase

Ref document number: 112019017514

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190822